Recognizing and treating secondary osteoporosis

Nature Reviews Rheumatology

Volumn 8, Issue 8, 2012, Pages 480-492

  Walker Bone, Karen ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; AGENTS AFFECTING CARBOHYDRATE METABOLISM; ALENDRONIC ACID; ANDROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CLODRONIC ACID; DENOSUMAB; EXEMESTANE; GLUCOCORTICOID; INCRETIN; LEVOTHYROXINE; METFORMIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; THIAZOLINEDIONE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANDROGEN THERAPY; BONE DENSITY; CAUSAL ATTRIBUTION; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMUR FRACTURE; FRACTURE; FRAGILITY FRACTURE; GENETIC PREDISPOSITION; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; JAW OSTEONECROSIS; KLINEFELTER SYNDROME; METASTASIS; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCYTE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY OSTEOPOROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTEBRA FRACTURE;

ALCOHOLISM; BONE AND BONES; BONE DENSITY; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOGONADISM; MALE; MALNUTRITION; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SEX FACTORS;

EID: 84864575252     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.93     Document Type: Review

References (140)

1. Office of the Surgeon General (US). The frequency of bone disease in Bone health and Osteoporosis: A Report of the Surgeon General. (US Department of Health and Human Services, Rockville, MD, USA, 2004
2. British Orthopaedic Association. The Care of Patients with Fragility Fracture. (British Orthopaedic Association, UK, 2007
3. Harvey, N., Dennison, E. and Cooper, C. Osteoporosis: Impact on health and economics. Nat. Rev. Rheumatol. 6, 99-105 (2010
4. Ross, P. D., Davis, J. W., Epstein, R. S., Wasnich, R. D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med. 114, 919-923 (1991
5. Lindsay, R. et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285, 320-323 (2001
6. Cuddihy, M. T., Gabriel, S. E., Crowson, C. S., O'Fallon, W. M. and Melton, L. J. III. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporosis Int. 9, 469-475 (1999
7. Deutschmann, H. A. et al. Search for occult secondary osteoporosis: Impact of identified possible risk factors on bone mineral density. J. Int. Med. 252, 389-397 (2002
8. Caplan, G. A., Scane, A. C. and Francis, R. M. Pathogenesis of vertebral crush fractures in women. J. R. Soc. Med. 87, 200-202 (1994
9. Odabasi, E., Turan, M., Tekbas, F. and Kutlu, M. Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: A retrospective study. Arch. Gynecol. Obstet. 279, 863-867 (2009
10. Moreira Kulak, C. A. et al. Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr. Pract. 6, 296-304 (2000
11. Tannenbaum, C. et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J. Clin. Endocrinol. Metab. 87, 4431-4437 (2002
12. Peris, P. et al. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin. Arthritis Rheum. 32, 64-70 (2002
13. Cerdá Gabaroi, D. et al. Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17, 135-139 (2010
14. Baillie, S. P., Davison, C. E., Johnson, F. J. and Francis, R. M. Pathogenesis of vertebral crush fractures in men. Age Ageing 21, 139-141 (1992
15. Khosla, S., Lufkin, E. G., Hodgson, S. F., Fitzpatrick, L. A. and Melton, L. J. III. Epidemiology and clinical features of osteoporosis in young individuals. Bone 15, 551-555 (1994)
16. Poór, G., Atkinson, E. J., O'Fallon, W. M. and Melton, L. J. III. Predictors of hip fractures in elderly men. J. Bone Miner. Res. 10, 1900-1907 (1995
17. Kelepouris, N., Harper, K. D., Gannon, F., Kaplan, F. S. and Haddad, J. G. Severe osteoporosis in men. Ann. Intern. Med. 123, 452-460 (1995
18. Grisso, J. A. et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am. J. Epidemiol. 145, 786-793 (1997
19. Scane, A. C. et al. Case-control study if the pathogenesis and sequelae of symptomatic vertebral fractures in men. Osteoporos. Int. 9, 91-97 (1999
20. Evans, S. F. and Davie, M. W. Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men. Ann. Rheum. Dis. 59, 269-275 (2000
21. Tuck, S. P., Raj, N. and Summers, J. D. Is distal forearm fracture in men due to osteoporosis? Osteoporos. Int. 13, 630-636 (2002
22. Pye, S. R. et al. Frequency and causes of osteoporosis in men. Rheumatology (Oxford) 42, 811-812 (2003
23. Ryan, C. S., Petkov, V. I. and Adler, R. A. Osteoporosis in men: The value of laboratory testing. Osteoporosis Int. 22, 1845-1853 (2011
24. Brown, S. E. Rethinking "primary" osteoporosis: Isn't all osteoporosis really just "secondary" osteoporosis? Better Bones [online] http://www.betterbones.com/osteoporosis/secondaryosteoporosis.aspx (2012
25. Romagnoli, E. et al. Secondary osteoporosis in men and women: Clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671-1679 (2011
26. Gallagher, J. C. and Sai, A. J. Is screening for secondary causes of osteoporosis worthwhile? Nat. Rev. Endocrinol. 6, 360-362 (2010
27. Rubin, M. R. et al. Idiopathic osteoporosis in premenopausal women. Osteoporosis Int. 16, 526-533 (2005
28. Dent, C. E. and Friedman, M. Idiopathic juvenile osteoporosis. Q. J. Med. 34, 177-210 (1965
29. Rauch, F. and Bishop, N. Juvenile osteoporosis in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, (ed. Rosen, C. J.) 264-267 (American Society for Bone Mineral Research, Washington, USA, 2008
30. Brodsky, B. and Baum, J. Modelling collagen diseases: Structural biology. Nature 453, 998-999 (2008
31. Sillence, D. O., Senn, A. and Danks, D. M. Genetic heterogeneity in Osteogenesis imperfecta. J. Med. Genet. 16, 101-116 (1979
32. Marini, J. C., Cabral, W. A. and Barnes, A. M. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 339, 59-70 (2010
33. Phillipi, C. A., Remmington, T. and Steiner, R. D. Bisphosphonate therapy for Osteogenesis imperfecta. Cochrane Database of Systematic Reviews Issue 4, Art. No.:CD005088. http://dx.doi.org/10.1002/14651858.CD005088.pub2.
34. Adami, S. et al. Intravenous neridronate in adults with osteogenesis imperfecta. J. Bone Miner. Res. 18, 126-130 (2003
35. Sakkers, R. et al. Skeletal effects and functional outcome with olpadronate in children with Osteogenesis imperfecta: A 2 year randomised placebo-controlled study. Lancet 363, 1427-1431 (2004
36. Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV Osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977-986 (2005
37. Ward, L. M. et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: A randomized placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 355-364. (2011
38. Papapoulos, S. E. and Cremers, S. C. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 356 1075-1076 (2007
39. Buntain, H. M. et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 61, 146-154 (2006
40. Haworth, C. S. et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 57, 719-723 (2002
41. Bhudhikanok, G. S. et al. Bone acquisition and loss in children and adults with cystic fibrosis: A longitudinal study. J. Paediatr. 133, 18-27 (1998
42. Haworth, C. S. Impact of cystic fibrosis on bone health. Curr. Opin. Pulm. Med. 16, 616-622 (2010
43. Sermet-Gaudelaus, I. et al. Low bone mineral density in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 951-957 (2007
44. Dif, F. et al. Severe osteopenia in CTFR-null mice. Bone 35, 595-603 (2004
45. Shead, E. F. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62, 650-651 (2007
46. Wolfenden, L. L. et al. Vitamin D and bone health in adults with cystic fibrosis. Clin. Endocrinol. 69, 374-381 (2008
47. Papaioannou, A. et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult Cystic fibrosis patients (CFOS trial). Chest 134, 794-800 (2008
48. Aris, R. M. et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am. J. Respir. Crit. Care Med. 169, 77-82 (2004
49. Chapman, I. et al. Intravenous Zoledronate improves bone density in adults with cystic fibrosis. Clin. Endocrinol. 70, 838-846 (2009
50. Haworth, C. S. et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 56, 314-316 (2001
51. Bojesen, A. et al. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers but not directly by testosterone. Osteoporosis Int. 22, 1441-1450 (2011
52. Swerdlow, A. J., Higgins, C. D., Schoemaker, M. J., Wright, A. F. and Jacobs, P. A. Mortality in patients with Klinefelter syndrome in Britain: A cohort study. J. Clin. Endocrinol. Metab. 90, 6516-6522 (2005
53. Ferlin, A., Schipilliti, M. and Foresta, C. Bone density and risk of osteoporosis in Klinefelter syndrome. Acta Paediatrica 100, 878-884 (2011
54. Ferlin, A. et al. Bone mass in subjects with Klinefelter syndrome: Role of testosterone levels and androgen receptor gene CAG polymorphism. J. Clin. Endocrinol. Metab. 96, E739-E745 (2011
55. Eastell, R. et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J. Intern. Med. 244, 271-292 (1998
56. Kanis, J. A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19, 893-899 (2004
57. Weinstein, R. S. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62-70 (2011
58. Hofbauer, L. C., Hamann, C. and Ebeling, P. Approach to the patient with secondary osteoporosis. Eur. J. Endocrinol. 162, 1009-1020 (2010
59. O'Brien, C. A. et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835-1841 (2004
60. Weinstein, R. S. Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone 46, 564-570 (2010
61. Russcher, H. et al. Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J. Clin. Endocrinol. Metab. 90, 5804-5810 (2005
62. Van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. and Cooper, C. Use of oral corticosteroids and risk of fractures. June, 2000. J. Bone Miner. Res. 20, 1487-1494 (2005
63. Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B. and Cooper, C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatology (Oxford) 39, 1383-1389 (2000
64. Van Staa, T. P., Leufkens, H. G. M., Cooper, C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16, 581-588 (2001
65. Cooper, M. S. et al. Osteoblastic 11β-hydroxysteroid dehydrogenase type I activity increases with age and glucocorticoid exposure. J. Bone Miner. Res. 17, 979-986 (2002
66. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. Royal College of Physicians [online]. http://bookshop.rcplondon.ac.uk/contents/pub89 a953a6c0 06c0 46d8 b79 e951536d9070.pdf (2003
67. Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515-1526 (2010
68. Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253-1263 (2009
69. Mok, C. C. et al. Extended report: Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomized double-blinded placebo-controlled trial. Ann. Rheum. Dis. 70, 778-784 (2011
70. Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty six month results of a randomised, double-blind, controlled trial. Arthritis Rheum. 60, 3346-3355 (2009
71. Lau, A. N. and Adachi, J. D. Role of teriparatide in treatment of glucocorticoid-induced osteoporosis. Ther. Clin. Risk Manag. 6, 497-503 (2010
72. Devogelaer, J. P. et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141-148 (2010
73. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039 (2007
74. Bassett, J. H. et al. Thyroid status during skeletal development determines adult bone structure and mineralization. Mol. Endocrinol. 21, 1893-1904 (2007
75. Cooper, M. S., Gittoes and N. J. L. Bone health and thyroid disease. Osteoporosis Rev. 18, 1-6 (2010
76. Cummings, S. R., Nevitt, M. C. and Browner, W. S. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332, 767-773 (1995
77. Bauer, D. C., Ettinger, B., Nevitt, M. C. and Stone, K. L. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 134, 561-568 (2001
78. Flynn, R. W. et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J. Clin. Endocrinol. Metab. 95, 186-193 (2010
79. Turner, M. R. et al. Levothyroxine dose and risk of fractures in older adults: Nested case-control study. BMJ 342, d2238 (2011
80. Nicodemus, K. K. and Folsom, A. R. Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 24, 1192-1197 (2001
81. Hofbauer, L. C., Brucck, C. C., Singh, S. K. and Dobnig, H. Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res. 22, 1317-1328 (2007
82. Thrailkill, K. M., Lumpkin, C. K. Jr, Bunn, R. C., Kemp, S. F. and Fowkles, J. L. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am. J. Physiol. Endocrinol. Metab. 289, E735-E745 (2005
83. De Liefde, I. I. et al. Bone mineral density and fracture risk in type II diabetes mellitus: The Rotterdam study. Osteoporosis Int. 16, 1713-1720 (2005
84. Holst, J. J. et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 13, 89-94 (2011
85. Venken, K., Boonen, S., Bouillon, R. and Vanderschueren, D. Gonadal steroids 117-123 in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (American Society of Bone Mineral Research, USA, 2008
86. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. and Goodwin, J. S. Risk of fracture after androgen deprivation therapy for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005
87. Morgans, A. K. and Smith, M. R. RANKL-targeted therapies: The next frontier in the treatment of male osteoporosis. J. Osteoporos. http://dx.doi.org/10.4061/2011/941310.
88. Smith, M. R. et al. Effects of Denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 182, 2670-2675 (2009
89. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised double-blind study. Lancet 377, 813-822 (2011
90. Ferrari-Lacraz, S. and Ferrari, S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporosis Int. 22, 435-446 (2011
91. Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008
92. Geusens, P. P. et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54, 1772-1777 (2006
93. Kong, Y. Y. et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999
94. Wheater, G. et al. Suppression of bone turnover by B cell depletion in patients with rheumatoid arthritis. Osteoporos. Int. 22, 3067-3072 (2011
95. Lodder, M. C. et al. Bone mineral density in patients with rheumatoid arthritis: Relation between disease severity and low bone mineral density. Ann. Rheum. Dis. 63, 1576-1580 (2004
96. Diarra, D. et al. Dickkopf 1 is a master regulator of joint remodelling. Nat. Med. 13, 156-163 (2007
97. Goldring, S. R. and Goldring, M. B. Eating bone or adding it: The wnt pathway decides. Nat. Med. 13, 133-134 (2007
98. Goldring, S. R. Inflammation-induced bone loss in the rheumatic diseases. In Primer on the Metabolic Bone Diseases (ed. Rosen, C. J.) 272-275 (American Society for Bone and Mineral Research, Washington, US, 2008
99. Goldring, S. R. and Gravallese, E. M. Bisphosphonates: Environmental protection for the joint? Arthritis Rheum. 50, 2044-2047 (2004
100. Ali, T., Lam, D., Bronze, M. S. and Humphrey, M. B. Osteoporosis in inflammatory bowel disease. Am. J. Med. 122, 599-604 (2009
101. Compston, J. E. et al. Osteoporosis in patients with inflammatory bowel disease. Gut 28, 410-415 (1987
102. Bernstein, C. N., Sargent, M. and Leslie, W. D. Serum osteoprotegerin is increased in Crohn's disease: A population-based case control study. Inflamm. Bowel Dis. 11, 325-330 (2005
103. Moschen, A. R. et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54, 479-487 (2005
104. Bernstein, C. N., Leslie, W. D. and Leboff, M. S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 124, 795-841 (2003
105. Henderson, S., Hoffman, N. and Prince, R. A double-blind placebo-controlled study of the effects of the bisphosphonates risedronate on bone mass in patients with inflammatory bowel disease. Am. J. Gastroenterol. 101, 119-123 (2006
106. Palomba, S. et al. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: A prospective, parallel, open-label, two-year extension study. Menopause 15, 730-736 (2008
107. Tebas, P. et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14, F63-F67 (2000
108. Moore, A. L. et al. Reduced bone mineral density in HIV-positive individuals. AIDS 15, 1731-1733 (2001
109. Brown, T. T. and Qaqish, R. B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 20, 2165-2174 (2006
110. Van Vonderen, M. G. et al. First line zidovudine/lamivudine/lopinavir/ ritonavir leads to greater bone loss compared with nevirapine/lopinavir/ ritonavir. AIDS 23, 1367-1376 (2009
111. Bruera, D., Luna, N., David, D. O., Bergoglio, L. M. and Zamudio, J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17, 1917-1923 (2003
112. Mondy, K. et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin. Infect. Dis. 36, 482-490 (2003
113. Dolan, S. E., Kanter, J. R. and Grinspoon, S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J. Clin. Endocrinol. Metab. 91, 2938-2945 (2006
114. Fausto, A. et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38, 893-897 (2006
115. Cotter, E. J., Ip, H. S., Powderly, W. G. and Doran, P. P. Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskelet. Disord. 9, 33 (2008
116. Fakruddin, J. M. and Laurence, J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor ? B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-?/RANKL cross-talk. J. Biol. Chem. 278, 48251-48258 (2003
117. Glesby, M. J. Bone disorders in Human Immunodeficiency Virus Infection. Clin. Infect. Dis. 37 (Suppl 2), S91-S95 (2003
118. Mallon, P. W. HIV and bone mineral density. Curr. Opin. Infect. Dis. 23, 1-8 (2010
119. Lin, D. and Rieder, M. J. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database of Systematic Reviews 2007, Issue 2. Art No.:CD005645. doi:10.1002/14651858. CD005645.pub2.
120. Callander, N. S. and Roodman, G. D. Myeloma bone disease. Semin. Haematol. 38, 276-285 (2001
121. Melton, L. J. III, Kyle, R. A., Achenbach, S. J., Oberg, A. L. and Rajkumar, S. V. Fracture risk with multiple myeloma: A population-based study. J. Bone Miner. Res. 20, 487-493 (2005
122. Tian, E. et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349, 2483-2494 (2003
123. Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 376, 1989-1999 (2010
124. Dore, R. K. The RANKL Pathway and Denosumab. Rheum. Dis. Clin. North Am. 37, 433-452 (2011
125. Giuliani, N. et al. The proteosome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110, 334-338 (2007
126. Vestergaard, P., Rejnmark, L. and Mosekilde, L. Proton pump inhibitors, Histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue Int. 79, 76-83 (2006
127. Yang, Y. X., Lewis, J. D., Epstein, S. and Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296, 2947-2953 (2006
128. O'Connell, M. B., Madden, D. M., Murray, A. M., Heaney, R. P. and Kerzner, L. J. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am. J. Med. 120, 778-781 (2005
129. Yu, E. W. et al. Acid-suppressive medications and risk of bone loss and fracture in postmenopausal women. Calcif. Tissue Int. 83, 251-259 (2008
130. Coleman, R. E. et al. Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol. 8, 119-127 (2007
131. Llombart, A. et al. Immediate administration of Zoledronic acid reduces aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E Zo FAST trial. Clin. Breast Cancer 12, 40-48 (2012
132. Sergi, G. et al. Preventive effect of risedronate on bone loss and frailty fractures in elderly women trated with anastrozole for early breast cancer. J. Bone Miner. Metab. http://dx.doi.org/10.1007/s00774-011-0341-1
133. Rizzoli, R. et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: An ESCEO position paper. Osteoporosis Int. http://dx.doi.org/10.1007/s00198-011- 1870-0
134. Schwartz, A. V. et al. Thiazolinedione use and bone loss in older diabetic patients. J. Clin. Endocrinol. Metab, 91, 3349-3354 (2006
135. Betteridge, D. J. Thiazolinediones and fracture risk in patients with Type 2 diabetes. Diabet. Med. 28, 759-771 (2011
136. Lecka-Czerniik, B. Bone loss in diabetes: use of antidiabetic thiazolinediones and secondary osteoporosis. Curr. Osteoporos. Rep, 8, 178-184 (2010
137. Meier, C. et al. Use of thiazolinediones and fracture risk. Arch. Intern. Med. 168, 820-825 (2008
138. Van Lierop, A. H. et al. Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical effects of bone turnover in men with type 2 diabetes mellitus. Eur. J. Endocrinol. 166, 711-716 (2012
139. Gustafson, B., Eliasson, B. and Smith, U. Thiazolinediones increase the wingless-type MMTV integration family (WNT) inhibitor Dickkopf 1 in adipocytes: A link with osteogenesis. Diabetologia 53, 536-540 (2010
140. Kanis, J. A. et al. FRAX® and its applications to clinical practice. Bone 44, 734-743 (2009